Filtros : "Clinical Therapeutics" Removido: "FCF004" Limpar

Filtros



Limitar por data


  • Fonte: Clinical Therapeutics. Unidades: FOB, FMRP

    Assuntos: FÁRMACOS, ANTIDEPRESSIVOS, HEMORRAGIA, SISTEMA GASTROINTESTINAL

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      FORGERINI, Marcela et al. Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study. Clinical Therapeutics, v. 45, n. 7, p. e159-e166, 2023Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2023.04.010. Acesso em: 29 jun. 2025.
    • APA

      Forgerini, M., Schiavo, G., Urbano, G., Nadai, T. R. de, Zapata-Cachafeiro, M., Herdeiro, M. T. F., & Mastroianni, P. de C. (2023). Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study. Clinical Therapeutics, 45( 7), e159-e166. doi:10.1016/j.clinthera.2023.04.010
    • NLM

      Forgerini M, Schiavo G, Urbano G, Nadai TR de, Zapata-Cachafeiro M, Herdeiro MTF, Mastroianni P de C. Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study [Internet]. Clinical Therapeutics. 2023 ; 45( 7): e159-e166.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2023.04.010
    • Vancouver

      Forgerini M, Schiavo G, Urbano G, Nadai TR de, Zapata-Cachafeiro M, Herdeiro MTF, Mastroianni P de C. Use of antidepressants and the risk of upper gastrointestinal tract bleeding: a case-control study [Internet]. Clinical Therapeutics. 2023 ; 45( 7): e159-e166.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2023.04.010
  • Fonte: Clinical Therapeutics. Unidade: FMRP

    Assuntos: GLAUCOMA, HIPERTENSÃO OCULAR, MEDICAMENTO

    Versão PublicadaAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      BELFORT JUNIOR, Rubens et al. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil. Clinical Therapeutics, v. 42, n. 2, p. 263-275, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2019.12.008. Acesso em: 29 jun. 2025.
    • APA

      Belfort Junior, R., Paula, J. S., Silva, M. J. L., Della Paolera, M., Kim, T., Chen, M. Y., & Goodkin, M. L. (2020). Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil. Clinical Therapeutics, 42( 2), 263-275. doi:10.1016/j.clinthera.2019.12.008
    • NLM

      Belfort Junior R, Paula JS, Silva MJL, Della Paolera M, Kim T, Chen MY, Goodkin ML. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil [Internet]. Clinical Therapeutics. 2020 ; 42( 2): 263-275.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.12.008
    • Vancouver

      Belfort Junior R, Paula JS, Silva MJL, Della Paolera M, Kim T, Chen MY, Goodkin ML. Fixed-combination bimatoprost/brimonidine/timolol in glaucom: a randomized, masked, controlled, phase III study conducted in Brazil [Internet]. Clinical Therapeutics. 2020 ; 42( 2): 263-275.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.12.008
  • Fonte: Clinical Therapeutics. Unidade: FCFRP

    Assuntos: SEGURANÇA DO PACIENTE, FÁRMACOS, FARMACOVIGILÂNCIA, MEDICAMENTO

    PrivadoAcesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      VARALLO, Fabiana Rossi et al. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication. Clinical Therapeutics, v. 41, n. 3, p. 598-603, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2019.01.013. Acesso em: 29 jun. 2025.
    • APA

      Varallo, F. R., Forgerini, M., Herdeiro, M. T. F., & Mastroianni, P. de C. (2019). Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication. Clinical Therapeutics, 41( 3), 598-603. doi:10.1016/j.clinthera.2019.01.013
    • NLM

      Varallo FR, Forgerini M, Herdeiro MTF, Mastroianni P de C. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication [Internet]. Clinical Therapeutics. 2019 ; 41( 3): 598-603.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.01.013
    • Vancouver

      Varallo FR, Forgerini M, Herdeiro MTF, Mastroianni P de C. Harmonization of pharmacovigilance regulation in Brazil: opportunities to improve risk communication [Internet]. Clinical Therapeutics. 2019 ; 41( 3): 598-603.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2019.01.013
  • Fonte: Clinical Therapeutics. Nome do evento: Conference of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Unidades: FMRP, FCFRP

    Assuntos: FARMACOCINÉTICA, FARMACOLOGIA, CONVULSÕES

    Como citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      ANTUNES, Natalícia de Jesus et al. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. Bridgewater: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo. . Acesso em: 29 jun. 2025. , 2013
    • APA

      Antunes, N. de J., Wichert-Ana, L., Coelho, E. B., Pasqua, O. D., Alexandre Júnior, V., Takayanagui, O. M., & Lanchote, V. L. (2013). Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. Bridgewater: Faculdade de Medicina de Ribeirão Preto, Universidade de São Paulo.
    • NLM

      Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Júnior V, Takayanagui OM, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. 2013 ; 35( 85): e76.[citado 2025 jun. 29 ]
    • Vancouver

      Antunes N de J, Wichert-Ana L, Coelho EB, Pasqua OD, Alexandre Júnior V, Takayanagui OM, Lanchote VL. Influence of verapamil on the pharmacokinetics of oxcarbazepine and 10-hydroxycarbazepine enantiomers in healthy volunteers. Clinical Therapeutics. 2013 ; 35( 85): e76.[citado 2025 jun. 29 ]
  • Fonte: Clinical Therapeutics. Unidade: FCF

    Assuntos: BIOEQUIVALÊNCIA, FARMACOCINÉTICA, CROMATOGRAFIA LÍQUIDA DE ALTA EFICIÊNCIA

    Acesso à fonteComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SILVA, Marina de Freitas et al. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers. Clinical Therapeutics, v. 32, n. 4, p. 758-765, 2010Tradução . . Disponível em: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf. Acesso em: 29 jun. 2025.
    • APA

      Silva, M. de F., Schramm, S. G., Kano, E. K., Koono, E. E. M., Porta, V., & Serra, C. H. dos R. (2010). Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers. Clinical Therapeutics, 32( 4), 758-765. Recuperado de http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
    • NLM

      Silva M de F, Schramm SG, Kano EK, Koono EEM, Porta V, Serra CH dos R. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers [Internet]. Clinical Therapeutics. 2010 ; 32( 4): 758-765.[citado 2025 jun. 29 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
    • Vancouver

      Silva M de F, Schramm SG, Kano EK, Koono EEM, Porta V, Serra CH dos R. Bioequivalence evaluation of single doses of two tramadol formulations: a randomized, open-label, two-period crossover study in healthy Brazilian volunteers [Internet]. Clinical Therapeutics. 2010 ; 32( 4): 758-765.[citado 2025 jun. 29 ] Available from: http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6VRS-4YYPPM6-H-1&_cdi=6242&_user=5674931&_pii=S0149291810001074&_orig=browse&_coverDate=04%2F30%2F2010&_sk=999679995&view=c&wchp=dGLzVzz-zSkzS&md5=39b0f577aa141d4e2b40edd118fdd7a3&ie=/sdarticle.pdf
  • Fonte: Clinical Therapeutics. Unidade: FCF

    Assuntos: BIOEQUIVALÊNCIA, ZIDOVUDINA (FARMACOCINÉTICA)

    Acesso à fonteDOIComo citar
    A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
    • ABNT

      SERRA, Cristina Helena dos Reis et al. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study. Clinical Therapeutics, v. 30, n. 5, p. 902-908, 2008Tradução . . Disponível em: https://doi.org/10.1016/j.clinthera.2008.05.003. Acesso em: 29 jun. 2025.
    • APA

      Serra, C. H. dos R., Koono, E. E. M., Kano, E. K., Schramm, S. G., Armando, Y. P., & Porta, V. (2008). Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study. Clinical Therapeutics, 30( 5), 902-908. doi:10.1016/j.clinthera.2008.05.003
    • NLM

      Serra CH dos R, Koono EEM, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study [Internet]. Clinical Therapeutics. 2008 ;30( 5): 902-908.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2008.05.003
    • Vancouver

      Serra CH dos R, Koono EEM, Kano EK, Schramm SG, Armando YP, Porta V. Bioequivalence and pharmacokinetics of two zidovudine formulations in healthy Brazilian volunteers: an open-label, randomized, single-dose, two-way crossover study [Internet]. Clinical Therapeutics. 2008 ;30( 5): 902-908.[citado 2025 jun. 29 ] Available from: https://doi.org/10.1016/j.clinthera.2008.05.003

Biblioteca Digital de Produção Intelectual da Universidade de São Paulo     2012 - 2025